Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers E > Headlines for EpiCept Corp. > News item |
Rodman starts EpiCept at market outperform
Rodman & Renshaw, LLC initiated its coverage of EpiCept Corp. with a market outperform rating and a 12-month target price of $6.00. Shares of the Englewood Cliffs, N.J., pharmaceutical company were down $0.07 or 2.40%, at $2.85 on volume of 122,254 shares versus the three-month running average of 61,690 shares. (Nasdaq: EPCT)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.